Comparative Pharmacology
Head-to-head clinical analysis: PENTIDS 400 versus VERSAPEN K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENTIDS 400 versus VERSAPEN K.
PENTIDS '400' vs VERSAPEN-K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking, leading to cell lysis.
VERSAPEN-K (hetacillin potassium) is a prodrug that is hydrolyzed to ampicillin, which inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
400 mg orally every 6 hours.
250-500 mg intramuscularly or intravenously every 6 hours for moderate infections; 1-2 g every 6 hours for severe infections.
None Documented
None Documented
0.5-1 hour in patients with normal renal function. Prolonged to 2-5 hours in renal impairment, requiring dose adjustment.
0.8-1.5 hours in adults with normal renal function (prolonged to 6-20 hours in severe renal impairment; dosing adjustment required when CrCl <30 mL/min).
Primarily renal (tubular secretion and glomerular filtration); 60-90% of dose excreted unchanged in urine within 24 hours. Minor biliary excretion (<10%) and fecal elimination.
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; biliary: 15-20% as active drug; fecal: <5%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic